cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma

Andrea Veronesi, Vittorina Zagonel, Mirella Santarossa, Umberto Tirelli, Enzo Galligioni, Mauro Gaetano Trovo, Salvatore Tumolo, Eligio Grigoletto

Research output: Contribution to journalArticlepeer-review

Abstract

From December 1981 to November 1982, a consecutive series of 37 patients with advanced non-oat cell bronchogenic carcinoma were treated with cis-platinum and etoposide in doses of 20 mg/m2 and 75 mg/m2, respectively, for 5 consecutive days every 3 weeks. Among the 33 evaluable patients, one complete response, 11 partial responses, five minor responses, seven unchanged states, and nine cases of progression were noted. Median duration of response was 30+ weeks. Toxicity was significant, but no treatment-related deaths were encountered. Combined cis-platinum and etoposide can provide significant palliation in approximately one-third of patients with the doses and schedule used.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume11
Issue number1
DOIs
Publication statusPublished - Aug 1983

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma'. Together they form a unique fingerprint.

Cite this